Roche's Zika test earns FDA emergency use authorization

The Food and Drug Administration granted emergency use authorization for a new Zika diagnostic test developed by Switzerland-based Roche.

Individuals who meet the CDC's clinical or epidemiologic criteria for testing can now be assessed using the LightMix Zika test. When used with compatible instruments, the test can analyze up to 96 plasma or serum samples, producing results within two and a half hours, according to Tech Times.

While the test has not earned FDA approval, the agency will permit the test's use as long as Zika remains a national public health concern.

The agency previously provided emergency use authorizations for several other Zika diagnostic tests within the past few months in an effort to control the spread of the virus.

More articles on supply chain:

Mylan to introduce generic EpiPen at half the price
Ex-Turing CEO Martin Shkreli injects himself into EpiPen debate, defends price hike
Senators ask FDA for EpiPen alternatives: 4 things to know

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.